Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribocicl...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1247270/full |
| _version_ | 1827782612605730816 |
|---|---|
| author | Marina Elena Cazzaniga Marina Elena Cazzaniga Antonio Ciaccio Antonio Ciaccio Romano Danesi Francois P. Duhoux Corrado Girmenia Kalhil Zaman Henrik Lindman Fabrizio Luppi Fabrizio Luppi Dimitrios Mavroudis Ida Paris Ayodele Olubukola Ahmed Samreen Christian Schem Christian Singer Anton Snegovoy |
| author_facet | Marina Elena Cazzaniga Marina Elena Cazzaniga Antonio Ciaccio Antonio Ciaccio Romano Danesi Francois P. Duhoux Corrado Girmenia Kalhil Zaman Henrik Lindman Fabrizio Luppi Fabrizio Luppi Dimitrios Mavroudis Ida Paris Ayodele Olubukola Ahmed Samreen Christian Schem Christian Singer Anton Snegovoy |
| author_sort | Marina Elena Cazzaniga |
| collection | DOAJ |
| description | The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient. |
| first_indexed | 2024-03-11T15:34:24Z |
| format | Article |
| id | doaj.art-b92d0fe6abaa453fb0590fe813591377 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T15:34:24Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b92d0fe6abaa453fb0590fe8135913772023-10-26T23:30:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-10-011310.3389/fonc.2023.12472701247270Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA projectMarina Elena Cazzaniga0Marina Elena Cazzaniga1Antonio Ciaccio2Antonio Ciaccio3Romano Danesi4Francois P. Duhoux5Corrado Girmenia6Kalhil Zaman7Henrik Lindman8Fabrizio Luppi9Fabrizio Luppi10Dimitrios Mavroudis11Ida Paris12Ayodele Olubukola13Ahmed Samreen14Christian Schem15Christian Singer16Anton Snegovoy17Phase 1 Research Unit, IRCCS San Gerardo dei Tintori, Monza (MB), ItalySchool of Medicine and Surgery, Milano Bicocca University, Monza (MB), ItalySchool of Medicine and Surgery, Milano Bicocca University, Monza (MB), ItalyGastroenterologic Unit, IRCCS San Gerardo dei Tintori, Monza (MB), ItalyDepartment Experimental and Clinical Medicine, University of Pisa, Pisa, ItalyCliniques Universitaires Saint-Luc, UC Louvain, Brussels, BelgiumDepartment of Hematology, Oncology and Dermatology, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, ItalyBreast Center, Department Of Oncology, Lausanne University Hospital CHUV, Lausanne, SwitzerlandDepartment Of Immunology, Genetics And Pathology, Uppsala University, Uppsala, SwedenSchool of Medicine and Surgery, Milano Bicocca University, Monza (MB), ItalyDivision Of Respiratory Diseases, Fondazione IRCCS San Gerardo Dei Tintori, Monza (MB), Italy0Department Of Medical Oncology, University Hospital Of Heraklion, Crete, Greece1Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy2University Hospitals of Leicester NHS Trust, Leicester, United Kingdom3University Hospitals Of Leicester Osborne Building, Leicester Royal Infirmary, Leicester, United Kingdom4MaHM Mammazentrum, Hamburg, Germany5Department Of Obstetrics & Gynecology Head, Center For Breast Health, Medical University of Vienna, Vienna, Austria6Department Of Oncology, University Of Medicine & Dentistry, Moscow, RussiaThe personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient.https://www.frontiersin.org/articles/10.3389/fonc.2023.1247270/fullCDK 4/6 inhibitorsabemaciclibribociclibpalbociclibdiarrhealiver toxicity and injury |
| spellingShingle | Marina Elena Cazzaniga Marina Elena Cazzaniga Antonio Ciaccio Antonio Ciaccio Romano Danesi Francois P. Duhoux Corrado Girmenia Kalhil Zaman Henrik Lindman Fabrizio Luppi Fabrizio Luppi Dimitrios Mavroudis Ida Paris Ayodele Olubukola Ahmed Samreen Christian Schem Christian Singer Anton Snegovoy Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project Frontiers in Oncology CDK 4/6 inhibitors abemaciclib ribociclib palbociclib diarrhea liver toxicity and injury |
| title | Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project |
| title_full | Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project |
| title_fullStr | Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project |
| title_full_unstemmed | Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project |
| title_short | Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project |
| title_sort | late onset toxicities associated with the use of cdk 4 6 inhibitors in hormone receptor positive hr human epidermal growth factor receptor 2 negative her2 metastatic breast cancer patients a multidisciplinary pan eu position paper regarding their optimal management the gioconda project |
| topic | CDK 4/6 inhibitors abemaciclib ribociclib palbociclib diarrhea liver toxicity and injury |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1247270/full |
| work_keys_str_mv | AT marinaelenacazzaniga lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT marinaelenacazzaniga lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT antoniociaccio lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT antoniociaccio lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT romanodanesi lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT francoispduhoux lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT corradogirmenia lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT kalhilzaman lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT henriklindman lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT fabrizioluppi lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT fabrizioluppi lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT dimitriosmavroudis lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT idaparis lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT ayodeleolubukola lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT ahmedsamreen lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT christianschem lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT christiansinger lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject AT antonsnegovoy lateonsettoxicitiesassociatedwiththeuseofcdk46inhibitorsinhormonereceptorpositivehrhumanepidermalgrowthfactorreceptor2negativeher2metastaticbreastcancerpatientsamultidisciplinarypaneupositionpaperregardingtheiroptimalmanagementthegiocondaproject |